Cepheid PT Raised to $40.00 at UBS AG (CPHD)
Analysts at UBS AG raised their price objective on shares of Cepheid (NASDAQ:CPHD) from $39.00 to $40.00 in a research report issued to clients and investors on Monday, AnalystRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. UBS AG’s target price would indicate a potential upside of 9.35% from the company’s current price.
CPHD has been the subject of a number of other recent research reports. Analysts at Zacks downgraded shares of Cepheid from a “neutral” rating to an “underperform” rating in a research note to investors on Tuesday, August 6th. They now have a $33.00 price target on the stock. Separately, analysts at Wedbush cut their price target on shares of Cepheid from $40.00 to $37.00 in a research note to investors on Friday, July 19th. They now have an “outperform” rating on the stock. Finally, analysts at Raymond James cut their price target on shares of Cepheid from $43.00 to $42.00 in a research note to investors on Friday, July 19th. They now have an “outperform” rating on the stock.
Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company. Cepheid presently has an average rating of “Hold” and an average target price of $40.47.
Shares of Cepheid (NASDAQ:CPHD) traded up 2.29% on Monday, hitting $36.58. 322,486 shares of the company’s stock traded hands. Cepheid has a one year low of $28.12 and a one year high of $40.70. The stock’s 50-day moving average is $35.11 and its 200-day moving average is $36.30. The company’s market cap is $2.467 billion.
Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Thursday, July 18th. The company reported $0.02 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.04 by $0.02. The company had revenue of $96.00 million for the quarter, compared to the consensus estimate of $92.57 million. During the same quarter last year, the company posted $0.11 earnings per share. Cepheid’s revenue was up 18.5% compared to the same quarter last year. Analysts expect that Cepheid will post $-0.26 EPS for the current fiscal year.
In other Cepheid news, Director Robert Easton unloaded 7,500 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $35.01, for a total value of $262,575.00. Following the sale, the director now directly owns 79,124 shares of the company’s stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.